ReviewBioscience reports2026
From metabolic intermediary to neurotransmitter: purinergic signaling in neurophysiology and vulnerability of brain circuits.
Review in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purinergic signaling represents an ancient intercellular communication system. Operating at the interface between bioenergetic metabolism and damage detection, extracellular purines such as adenosine 5'-triphosphate (ATP) and adenosine (ADO) are recruited into the nervous system for neurotransmission and homeostatic control. Here, we discuss how purine-dependent mechanisms modulate excitation-inhibition balance, neuroplasticity, and neurodevelopment. In the hippocampus, ADO exerts inhibitory tonic functions, while ATP is released during high neuronal activity, being considered a destabilizing factor during pathological conditions. In the striatum, purinergic signaling intersects with dopaminergic and glutamatergic pathways in the fine-tuning of motor control, with ADO receptors modulating corticostriatal transmission and influencing vulnerability to excitotoxicity and neurodegeneration. Focusing on the cerebellum, we illustrate how purinergic signaling contributes to neurodevelopment and neuroplasticity, and how dysfunctions of the purinergic signaling system give rise to associated neuropathologies. In the brainstem, we demonstrate how purinergic signaling modulates autonomic and respiratory circuits to maintain cardiorespiratory homeostasis through astrocyte-neuron communication. Despite its adaptive value, purinergic signaling is optimized for transient, activity-, or damage-dependent activation. Thus, we argue that, under contemporary conditions characterized by chronic stress and extended lifespan, the purinergic signaling system may undergo a shift from predominantly acute to chronic engagement. This evolutionary mismatch may promote maladaptive purinergic activity, contributing to its involvement in synaptic dysfunction, neuroinflammation, and selective vulnerability of brain circuits. Moreover, we integrate evolutionary, neurophysiological, and neuropathological perspectives to propose purinergic signaling as a key mechanistic bridge linking neural function, bioenergetic metabolism, molecular pathways, and neurodegenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.